Table 2 Patient, tumor, and treatment characteristics ( N =26)
Characteristics | Disease group [No. (%)] | |
|---|---|---|
NPC (n=10) | Others (n=16) | |
Age (year) | ||
Median | 54 | 58.5 |
Range | 31-67 | 10-83 |
Gender | ||
Male:Female | 8 (80): 2 (20) | 12 (75): 4 (25) |
Sites treated with SBRT | ||
Nasopharynx and base of skull | 10 (100) | |
Nasal cavity and PNS | 8 (50) | |
Periorbit | 4 (25) | |
Tongue | 3 (18.8) | |
Oropharyngeal wall | 1 (6.2) | |
Pathology | ||
Type I NPC | 2 (20) | |
Type II NPC | 8 (80) | |
Squamous cell carcinoma | 7 (43.8) | |
Adenoid cystic carcinoma | 5 (31.3) | |
Chondrosarcoma | 2 (12.5) | |
Malignant melanoma | 1 (6.2) | |
Poorly differentiated adenocarcinoma | 1 (6.2) | |
Tumor T stage | ||
T4 | 7 (70) | 7 (43.8) |
T3 | 2 (20) | 4 (25) |
T2 | 1 (10) | 5 (31.2) |
Tumor N stage | ||
N2 | 3 (30) | 1 (6.3) |
N1 | 6 (60) | 2 (12.5) |
N0 | 1 (10) | 13 (81.2) |
Previous debulking surgery | ||
Yes:No | 0 (0):10 (100) | 11(68.8): 5 (31.2) |
Combined chemotherapy | ||
Yes:No | 10 (100): 0 (0) | 9 (56.3): 7 (43.7) |
SBRT GTV (cc) | ||
Median | 45.3 | 19.4 |
Range | 21.3-69.4 | 6.9-66.8 |
Prescription isodose line (%) | ||
Median | 80 | 80 |
Range | 70-80 | 70-85 |
EBRT dose (Gy) | ||
Median | 59.4 | 47.5 |
Range | 50.4-70.2 | 39.6-59.4 |
SBRT dose (Gy) | ||
Median | 21 | 22.5 |
Range | 18-25 | 10-25 |
SBRT fractional dose (Gy) | ||
Median | 6.5 | 5 |
Range | 5-7 | 3-8 |
Cumulative dose in BED10 (Gy) | ||
Median | 103.7 | 90.6 |
Range | 92-118.5 | 72.7-107.6 |